Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells

Molecular Cancer Therapeutics

Volumn 2, Issue 6, 2003, Pages 563-572

  Shi, Yijiang ^a   Gera, Joseph ^a   Hsu, Jung Hsin ^a   Van Ness, Brian ^b   Lichtenstein, Alan ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TRANSFERASE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIVISION; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MULTIPLE MYELOMA; MUTATION; ONCOGENE RAS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLOW CYTOMETRY; GENES, RAS; HUMANS; INTERLEUKIN-6; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; MUTATION; NF-KAPPA B; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRANSFECTION;

EID: 0142014637     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Prendergast, G. C. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr. Opin. Cell Biol., 12: 166-173, 2000. (Pubitemid 30142562)
2. Tamanoi, F., Gau, C-L., Jiang, C., Edamatsu, H., and Kato-Stankiewicz, J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci., 58: 1636-1649, 2001. (Pubitemid 32996099)
3. Sebti, S. M., and Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene, 19: 6584-6593, 2000. (Pubitemid 32197696)
4. Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D. M., Boccadoro, M., and Pileri, A. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81: 2708-2713, 1993. (Pubitemid 23147577)
5. Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., and Dalla-Favera, R. Ras oncogene mutation in multiple myeloma. J. Exp. Med., 170: 1715-1725, 1989. (Pubitemid 19284568)
6. Portier, M., Moles, J. P., Mazars, G. R., Jeanteur, B., Bataille, R., Klein, B., and Theillet, C. P53 and RAS gene mutations in multiple myeloma. Oncogene, 7: 2539-2543, 1992.
7. Liu, P., Quam, L., Billadeau, D., Kay, N. E., Greipp, P., Kyle, R. A., Oken, M. M., and Van Ness, B. Activating mutations of N- and K-ras in multiple myeloma show distinct clinical associations: analysis of the ECOG Phase III trial. Blood, 88: 2699-2706, 1996. (Pubitemid 26327523)
8. Reuter, C. W. M., Morgan, M. A., Dolp, O., and Bergmann, L. Potential effectiveness of inhibitors of ras signaling in the treatment of multiple myeloma. Proc. Amer. Assoc. Cancer Res., 43: 282a, 2001.
9. Mackley, P. A., Shain, K. H., Dalton, W. S., and Alsina, M. Farnesyl transferase inhibitor R115777 decreases AKT phosphorylation in multiple myeloma cell lines and its apoptotic effects correlate with phospho-AKT expression levels. Proc. Am. Soc. Hematol., 100: 810a, 2002.
10. Alsina, M., Overton, R., Belle, N., Wilson, E. F., Sullivan, D., Djulbegovic, B., Fonseca, R., Dalton, W. S., and Sebti, S. M. Farnesyl transferase inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Proc. Am. Assoc. Cancer Res., 43: 1000, 2002.
11. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
12. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
13. Billadeau, D., Jelinek, D., Shah, N., LeBien, T. W., and Van Ness, B. Introduction of an activated N-ras oncogene alters the growth characteristics of the IL-6-dependent myeloma cell line ANBL6. Cancer Res., 55:3640-3646, 1995.
14. Billadeau, D., Liu, P., Jelinek, D., Shah, N., LeBien, T., and Van Ness, B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res., 57: 2268-2275, 1997. (Pubitemid 27247048)
15. Rowley, M., Liu, P., and Van Ness, B. Heterogeneity in the therapeutic response of genetically altered myeloma cell lines to IL-6, dexamethasone, doxorubicin and melphalan. Blood, 96: 3175-3180, 2000.
16. Tu, Y., Gardner, A., and Lichtenstein, A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res., 60:6763-6770, 2000.
17. Lerner, E. C., Zhang, T-T., Knowles, D. B., Qian, Y., Hamilton, A. D., and Sebti, S. M. Inhibition of the prenylation of K-ras, but not H- or N-ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene, 15: 1283-1288, 1997. (Pubitemid 27429743)
18. Baldwin, A. S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Investig., 107: 241-246, 2001. (Pubitemid 32157954)
19. Hsu, J-h., Shi, Y., Hu, L., Fisher, M., Franke, T. F., and Lichtenstein, A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene, 21: 1391-1400, 2002. (Pubitemid 34214504)
20. Jelinek, D. F., Ahmann, G. J., Greipp, P. R., Jalal, S. M., Westendorf, J. J., Katzmann, J. A., Kyle, R. A., and Lust, J. A. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangements: clinical implications. Cancer Res., 53: 5320-5327, 1993. (Pubitemid 23333406)
21. Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., and Lewis, M. D. Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J. Biol. Chem., 268: 18415-18418, 1993. (Pubitemid 23273764)
22. Sinensky, M., Beck, L. A., Leonead, S., and Evans, R. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J. Biol. Chem., 265: 19937-19941, 1990. (Pubitemid 120013953)
23. Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A., and Kaufmann, S. H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res., 6: 2318-2325, 2000. (Pubitemid 30399198)
24. Hu, L., Shi, Y., Hsu, J-h., Gera, J., Van Ness, B., and Lichtenstein, A. Downstream effectors of oncogenic ras in multiple myeloma cells., Blood, 101: 3126-3135, 2003. (Pubitemid 36858006)
25. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-P38 MAP kinases on apoptosis. Science (Wash. DC), 270: 1326-1332, 1995.
26. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R. amd Franke, T. F. IL-3-dependent survival by the AKT protein kinase. Proc. Natl. Acad. Sci. USA, 94: 11345-11353, 1997.
27. Harada, H., Andersen, J. S., Mann, M., Terada, N., and Korsmeyer, S. J. P70S6kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA, 98: 9666-9670, 2001. (Pubitemid 32769360)
28. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature (Lond.), 376: 167-170, 1995.
29. Pullen, N., Dennis, P. B., Andjelkovic, M., Duffner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. Phosphorylation and activation of p70S6K by PDK1. Science (Wash. DC), 279: 707-710, 1998.
30. Du, W., Liu, A., and Prendergast, G. C. Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res., 59: 4208-4212, 1999. (Pubitemid 29418727)
31. Daeipour, M., Kumar, G., Amaral, M. C., and Nel, A. E. Recombinant IL-6 activates p42 and p44 MAP kinases in the IL-6-responsive B cell line AF-10. J. Immunol., 150: 4743-4752, 1993.
32. Ogata, A., Chauhan, D., Urashima, M., Teoh, G., Hatziyamma, M., Vidriades, M. B., Schlossman, S., and Anderson, K. IL-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated protein kinase cascade. J. Immunol., 159: 2212-2220, 1997.
33. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., and Pai, J-K. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997. (Pubitemid 27232866)
34. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene, 16: 1467-1473, 1998. (Pubitemid 28151853)
35. Suzuki, N., Urano, J., and Tamanoi, F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA, 95: 15356-15361, 1998. (Pubitemid 29018703)
36. Anderson, K., Jones, R. M., Morimoto, C., Leavitt, P., and Baruch, B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73: 1915-1922, 1989.
37. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of IL-6 for human multiple myeloma. Nature (Lond.), 332: 83-87, 1988.
38. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T. IL-6 family of cytokines and gp130. Blood, 86: 1243-1251, 1995.
39. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. Phosphatidylinositol-3-OH kinase as a direct target of ras. Nature (Lond.), 370: 527-532, 1994. (Pubitemid 24264918)
40. Mukhopadhyay, N. K., Price, D. J., Kyriakis, J. M., Pelech, S., Sanghera, J., and Avruch, J. An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70S6 kinase. J. Biol. Chem., 267: 3325-3335, 1992.
41. Feldkamp, M. M., Lau, N., Roncari, L., and Guha, A. Isotype-specific ras-GTP levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of ras mutational status. Cancer Res., 61: 4425-4431, 2001. (Pubitemid 32685770)
42. Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. Biol. Chem., 270: 26802-26806, 1995. (Pubitemid 3007240)
43. Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S., and Cheng, J. Q. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol., 20: 139-148, 2000. (Pubitemid 30002555)
44. Liu, A., and Prendergast, G. C. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of AKT kinase activity by farnesyltransferase inhibitors. FEBS Lett., 481: 205-208, 2000.
45. Liu, A., Du, W., Liu, J. P., Jessell, T. M., and Prendergast, G. C. RhoB alteration is necessary for apoptotic and anti-neoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol., 20: 6105-6113, 2000. (Pubitemid 30613058)
46. Edamatsu, H., Gau, C. L., Nemoto, T., Guo, L., and Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene, 19: 3059-3068, 2000. (Pubitemid 30438462)
47. Law, B. K., Norgaard, P., Gnudi, L., Kahn, B. B., Poulson, H. S., and Moses, H. L. Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70S6K pathway. J. Biol. Chem., 274: 4743-4748, 1999.